Core Insights - Mirxes Holding Company Limited has completed the enrollment for its prospective clinical study CADENCE CRC, marking a significant milestone as it transitions to laboratory analysis and data evaluation, with results expected by 2026 [1][2] Group 1: Study Overview - The CADENCE CRC study, initiated in 2023, aims to recruit 6,000 participants from diverse ethnic backgrounds in Southeast Asia, enhancing the universality and clinical relevance of the data [2] - This study utilizes colonoscopy as the gold standard to rigorously assess the effectiveness and safety of Mirxes' blood test for colorectal cancer, driven by its proprietary miRNA multi-omics platform [2] - CADENCE CRC is noted as the largest blood-based colorectal cancer screening clinical study in the ASEAN region, focusing on early screening, which differentiates it from other approved products in the market [2] Group 2: Market Context - The Asian colorectal cancer screening market has surpassed 100 billion yuan, with a growing demand for non-invasive, convenient, and precise blood tests, positioning Mirxes' offerings to fill a significant market gap [2][3] - Single cancer screening remains dominant in the global early screening market, supported by clear clinical evidence and regulatory pathways, while multi-cancer screening faces challenges in clinical validation [3] Group 3: Technological Advantage - Mirxes leverages its unique miRNA technology platform to differentiate itself in a competitive early screening landscape, achieving commercialization that few global companies have accomplished [4] - The company targets the ASEAN and China markets, addressing the low screening coverage due to accessibility and resource distribution issues, thereby establishing a comprehensive clinical and commercial network in Asia [4]